The number of people living with HIV/AIDS worldwide has reached 34 million.
But despite the importance of developing a vaccine for the disease, research groups and small biopharma companies are finding challenges in obtaining the amount of funding required to conduct effective research and clinical trials.
Robert McNally, CEO of GeoVax, an Atlanta-based company that is working on vaccines to fight and prevent HIV, explores this funding question in a new GHN Commentary.
“Why has the HIV/AIDS crisis diminished in the public consciousness, domestically and elsewhere, despite the continued high cost of present treatment regimens?’’ McNally writes.
Georgia Health News welcomes Commentary submissions. If you would like to propose a Commentary piece for Georgia Health News, please e-mail Andy Miller, editor of GHN, at firstname.lastname@example.org
No related posts.